Global Next Generation Sequencing Market

Next Generation Sequencing Comprehensive Study by Type (Targeted Sequencing & Resequencing, Whole Genome Sequencing, Whole Exome Sequencing), Application (Whole-genome Sequencing, Exome Sequencing, Targeted Resequencing, De Novo Sequencing, RNA Sequencing, ChIP Sequencing, Methyl Sequencing, Others), End-Users (Academic and Research Institutes, Hospitals and Clinics, Biotech and Pharma Companies, Others) Players and Region - Global Market Outlook to 2027

Next Generation Sequencing Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 18.8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Next Generation Sequencing Market Scope
Next-generation sequencing (NGS), alternatively known as high-throughput sequencing, allows sequencing of millions of DNA molecules simultaneously. This method is useful in the field of personalized medicine, genetic diseases and clinical diagnostics as it offers high throughput option with ability to perform sequencing for multiple individual at the same time. The NGS machine or NGS sequencer is flexible enough to operate tasks such as whole –genome sequencing (WGS), targeted sequencing and transcriptome analysis.

AttributesDetails
Study Period2017-2027
Base Year2021
High Growth MarketAsia Pacific
Largest MarketNorth America
UnitValue (USD Billion)
Key Companies ProfiledDNAnexus [United States], DNASTAR [United States], Eagle Genomics [United Kingdom], Edge Biosystems [United States], GENEWIZ [United States], Roche [Switzerland], Agilent Technologies [United States], Biomatters, Ltd [New Zealand], CLC Bio [Denmark], GATC biotech AG [Germany], Macrogen [South Korea], BGI (Beijing Genomics Institute) [China], Illumina [United States], Life Technology Corporation [United States], EMC Corporation [United States] and Dnastar [United States]
CAGR18.8%


"According to AMA, the Global Next Generation Sequencing market is expected to see growth rate of 18.8% and may see market size of USD12.8 Billion by 2027."

Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Next Generation Sequencing market throughout the predicted period.

DNAnexus [United States], DNASTAR [United States], Eagle Genomics [United Kingdom], Edge Biosystems [United States], GENEWIZ [United States], Roche [Switzerland], Agilent Technologies [United States], Biomatters, Ltd [New Zealand], CLC Bio [Denmark], GATC biotech AG [Germany], Macrogen [South Korea], BGI (Beijing Genomics Institute) [China], Illumina [United States], Life Technology Corporation [United States], EMC Corporation [United States] and Dnastar [United States] are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Thermo Fisher Scientific, Inc [United States], Pacific Biosciences of California, Inc [United States], Oxford Nanopore Technologies, Ltd. [United Kingdom], Eurofins Scientific [Luxembourg], PerkinElmer [United States], Qiagen [Netherlands], 454 Life Sciences [United States] and PierianDx [United States].

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Next Generation Sequencing market by Type , by Application (Whole-genome Sequencing, Exome Sequencing, Targeted Resequencing, De Novo Sequencing, RNA Sequencing, ChIP Sequencing, Methyl Sequencing and Others) and Region with country level break-up.

On the basis of geography, the market of Next Generation Sequencing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2021. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement.

Market Leaders and their expansionary development strategies
September 2018 - : Brooks Automation Buys GENEWIZ to expand Genomics footprint. GENEWIZ has significant growth prospects in next-gen and Sanger sequencing market. The transaction is expected to be over by end of 2018.
Recently in March 2018, ARUP and metagenomics company IDbyDNA, Inc. launched Explify Respiratory which is an NGS test for respiratory infections that helps physicians while diagnosing patients with pneumonia and other respiratory diseases. Using nucleic acid the test identifies over 200 common and rare bacteria and viruses.
The United States Food and Drug Administration finalized two guidelines to accelerate the development of reliable, beneficial next generation sequencing-based tests. "The new policies provide a modern and flexible framework to generate data needed to support the FDA’s review of NGS-based tests, and give developers new tools to support the efficient development and validation of these technologies" said FDA Commissioner Scott Gottlieb, M.D.

Influencing Trend:
Development in Portable Sequencing Technology and Adoption and Integration of Advanced LIMS (Laboratory Information Management System) Real-Time Tracking Methods

Market Growth Drivers:
Technical Advancement in NGS platform and Ability to Provide Cost Effective Solution

Challenges:
Issue Related to Ethics and Problem Associated With Interpretation of Complex Data

Restraints:
Lack of Budget in Emerging Economies and Lack of Awareness About NGS Technology

Opportunities:
Favorable Government Initiatives and Incorporation of Big Data

Key Target Audience
Healthcare Industry, NGS Service Providers, Potential Investors, Research Institute, Government Agencies and Others

Report Objectives / Segmentation Covered

By Type
  • Targeted Sequencing & Resequencing
  • Whole Genome Sequencing
  • Whole Exome Sequencing
By Application
  • Whole-genome Sequencing
  • Exome Sequencing
  • Targeted Resequencing
  • De Novo Sequencing
  • RNA Sequencing
  • ChIP Sequencing
  • Methyl Sequencing
  • Others
By End-Users
  • Academic and Research Institutes
  • Hospitals and Clinics
  • Biotech and Pharma Companies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Technical Advancement in NGS platform
      • 3.2.2. Ability to Provide Cost Effective Solution
    • 3.3. Market Challenges
      • 3.3.1. Issue Related to Ethics
      • 3.3.2. Problem Associated With Interpretation of Complex Data
    • 3.4. Market Trends
      • 3.4.1. Development in Portable Sequencing Technology
      • 3.4.2. Adoption and Integration of Advanced LIMS (Laboratory Information Management System) Real-Time Tracking Methods
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Next Generation Sequencing, by Type, Application, End-Users and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Next Generation Sequencing (Value)
      • 5.2.1. Global Next Generation Sequencing by: Type (Value)
        • 5.2.1.1. Targeted Sequencing & Resequencing
        • 5.2.1.2. Whole Genome Sequencing
        • 5.2.1.3. Whole Exome Sequencing
      • 5.2.2. Global Next Generation Sequencing by: Application (Value)
        • 5.2.2.1. Whole-genome Sequencing
        • 5.2.2.2. Exome Sequencing
        • 5.2.2.3. Targeted Resequencing
        • 5.2.2.4. De Novo Sequencing
        • 5.2.2.5. RNA Sequencing
        • 5.2.2.6. ChIP Sequencing
        • 5.2.2.7. Methyl Sequencing
        • 5.2.2.8. Others
      • 5.2.3. Global Next Generation Sequencing by: End-Users (Value)
        • 5.2.3.1. Academic and Research Institutes
        • 5.2.3.2. Hospitals and Clinics
        • 5.2.3.3. Biotech and Pharma Companies
        • 5.2.3.4. Others
      • 5.2.4. Global Next Generation Sequencing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Next Generation Sequencing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. DNAnexus [United States]
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. DNASTAR [United States]
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eagle Genomics [United Kingdom]
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Edge Biosystems [United States]
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GENEWIZ [United States]
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Roche [Switzerland]
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Agilent Technologies [United States]
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biomatters, Ltd [New Zealand]
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. CLC Bio [Denmark]
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GATC biotech AG [Germany]
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Macrogen [South Korea]
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. BGI (Beijing Genomics Institute) [China]
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Illumina [United States]
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Life Technology Corporation [United States]
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. EMC Corporation [United States]
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Dnastar [United States]
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
  • 7. Global Next Generation Sequencing Sale, by Type, Application, End-Users and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Next Generation Sequencing (Value)
      • 7.2.1. Global Next Generation Sequencing by: Type (Value)
        • 7.2.1.1. Targeted Sequencing & Resequencing
        • 7.2.1.2. Whole Genome Sequencing
        • 7.2.1.3. Whole Exome Sequencing
      • 7.2.2. Global Next Generation Sequencing by: Application (Value)
        • 7.2.2.1. Whole-genome Sequencing
        • 7.2.2.2. Exome Sequencing
        • 7.2.2.3. Targeted Resequencing
        • 7.2.2.4. De Novo Sequencing
        • 7.2.2.5. RNA Sequencing
        • 7.2.2.6. ChIP Sequencing
        • 7.2.2.7. Methyl Sequencing
        • 7.2.2.8. Others
      • 7.2.3. Global Next Generation Sequencing by: End-Users (Value)
        • 7.2.3.1. Academic and Research Institutes
        • 7.2.3.2. Hospitals and Clinics
        • 7.2.3.3. Biotech and Pharma Companies
        • 7.2.3.4. Others
      • 7.2.4. Global Next Generation Sequencing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Next Generation Sequencing: by Type(USD Billion)
  • Table 2. Next Generation Sequencing Targeted Sequencing & Resequencing , by Region USD Billion (2016-2021)
  • Table 3. Next Generation Sequencing Whole Genome Sequencing , by Region USD Billion (2016-2021)
  • Table 4. Next Generation Sequencing Whole Exome Sequencing , by Region USD Billion (2016-2021)
  • Table 5. Next Generation Sequencing: by Application(USD Billion)
  • Table 6. Next Generation Sequencing Whole-genome Sequencing , by Region USD Billion (2016-2021)
  • Table 7. Next Generation Sequencing Exome Sequencing , by Region USD Billion (2016-2021)
  • Table 8. Next Generation Sequencing Targeted Resequencing , by Region USD Billion (2016-2021)
  • Table 9. Next Generation Sequencing De Novo Sequencing , by Region USD Billion (2016-2021)
  • Table 10. Next Generation Sequencing RNA Sequencing , by Region USD Billion (2016-2021)
  • Table 11. Next Generation Sequencing ChIP Sequencing , by Region USD Billion (2016-2021)
  • Table 12. Next Generation Sequencing Methyl Sequencing , by Region USD Billion (2016-2021)
  • Table 13. Next Generation Sequencing Others , by Region USD Billion (2016-2021)
  • Table 14. Next Generation Sequencing: by End-Users(USD Billion)
  • Table 15. Next Generation Sequencing Academic and Research Institutes , by Region USD Billion (2016-2021)
  • Table 16. Next Generation Sequencing Hospitals and Clinics , by Region USD Billion (2016-2021)
  • Table 17. Next Generation Sequencing Biotech and Pharma Companies , by Region USD Billion (2016-2021)
  • Table 18. Next Generation Sequencing Others , by Region USD Billion (2016-2021)
  • Table 19. South America Next Generation Sequencing, by Country USD Billion (2016-2021)
  • Table 20. South America Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 21. South America Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 22. South America Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 23. Brazil Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 24. Brazil Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 25. Brazil Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 26. Argentina Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 27. Argentina Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 28. Argentina Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 29. Rest of South America Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 30. Rest of South America Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 31. Rest of South America Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 32. Asia Pacific Next Generation Sequencing, by Country USD Billion (2016-2021)
  • Table 33. Asia Pacific Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 34. Asia Pacific Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 35. Asia Pacific Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 36. China Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 37. China Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 38. China Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 39. Japan Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 40. Japan Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 41. Japan Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 42. India Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 43. India Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 44. India Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 45. South Korea Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 46. South Korea Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 47. South Korea Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 48. Taiwan Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 49. Taiwan Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 50. Taiwan Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 51. Australia Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 52. Australia Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 53. Australia Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 54. Rest of Asia-Pacific Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 55. Rest of Asia-Pacific Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 56. Rest of Asia-Pacific Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 57. Europe Next Generation Sequencing, by Country USD Billion (2016-2021)
  • Table 58. Europe Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 59. Europe Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 60. Europe Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 61. Germany Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 62. Germany Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 63. Germany Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 64. France Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 65. France Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 66. France Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 67. Italy Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 68. Italy Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 69. Italy Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 70. United Kingdom Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 71. United Kingdom Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 72. United Kingdom Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 73. Netherlands Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 74. Netherlands Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 75. Netherlands Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 76. Rest of Europe Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 77. Rest of Europe Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 78. Rest of Europe Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 79. MEA Next Generation Sequencing, by Country USD Billion (2016-2021)
  • Table 80. MEA Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 81. MEA Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 82. MEA Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 83. Middle East Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 84. Middle East Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 85. Middle East Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 86. Africa Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 87. Africa Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 88. Africa Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 89. North America Next Generation Sequencing, by Country USD Billion (2016-2021)
  • Table 90. North America Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 91. North America Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 92. North America Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 93. United States Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 94. United States Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 95. United States Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 96. Canada Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 97. Canada Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 98. Canada Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 99. Mexico Next Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 100. Mexico Next Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 101. Mexico Next Generation Sequencing, by End-Users USD Billion (2016-2021)
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Next Generation Sequencing: by Type(USD Billion)
  • Table 119. Next Generation Sequencing Targeted Sequencing & Resequencing , by Region USD Billion (2022-2027)
  • Table 120. Next Generation Sequencing Whole Genome Sequencing , by Region USD Billion (2022-2027)
  • Table 121. Next Generation Sequencing Whole Exome Sequencing , by Region USD Billion (2022-2027)
  • Table 122. Next Generation Sequencing: by Application(USD Billion)
  • Table 123. Next Generation Sequencing Whole-genome Sequencing , by Region USD Billion (2022-2027)
  • Table 124. Next Generation Sequencing Exome Sequencing , by Region USD Billion (2022-2027)
  • Table 125. Next Generation Sequencing Targeted Resequencing , by Region USD Billion (2022-2027)
  • Table 126. Next Generation Sequencing De Novo Sequencing , by Region USD Billion (2022-2027)
  • Table 127. Next Generation Sequencing RNA Sequencing , by Region USD Billion (2022-2027)
  • Table 128. Next Generation Sequencing ChIP Sequencing , by Region USD Billion (2022-2027)
  • Table 129. Next Generation Sequencing Methyl Sequencing , by Region USD Billion (2022-2027)
  • Table 130. Next Generation Sequencing Others , by Region USD Billion (2022-2027)
  • Table 131. Next Generation Sequencing: by End-Users(USD Billion)
  • Table 132. Next Generation Sequencing Academic and Research Institutes , by Region USD Billion (2022-2027)
  • Table 133. Next Generation Sequencing Hospitals and Clinics , by Region USD Billion (2022-2027)
  • Table 134. Next Generation Sequencing Biotech and Pharma Companies , by Region USD Billion (2022-2027)
  • Table 135. Next Generation Sequencing Others , by Region USD Billion (2022-2027)
  • Table 136. South America Next Generation Sequencing, by Country USD Billion (2022-2027)
  • Table 137. South America Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 138. South America Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 139. South America Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 140. Brazil Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 141. Brazil Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 142. Brazil Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 143. Argentina Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 144. Argentina Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 145. Argentina Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 146. Rest of South America Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 147. Rest of South America Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 148. Rest of South America Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 149. Asia Pacific Next Generation Sequencing, by Country USD Billion (2022-2027)
  • Table 150. Asia Pacific Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 151. Asia Pacific Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 152. Asia Pacific Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 153. China Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 154. China Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 155. China Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 156. Japan Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 157. Japan Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 158. Japan Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 159. India Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 160. India Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 161. India Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 162. South Korea Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 163. South Korea Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 164. South Korea Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 165. Taiwan Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 166. Taiwan Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 167. Taiwan Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 168. Australia Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 169. Australia Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 170. Australia Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 171. Rest of Asia-Pacific Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 172. Rest of Asia-Pacific Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 173. Rest of Asia-Pacific Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 174. Europe Next Generation Sequencing, by Country USD Billion (2022-2027)
  • Table 175. Europe Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 176. Europe Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 177. Europe Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 178. Germany Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 179. Germany Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 180. Germany Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 181. France Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 182. France Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 183. France Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 184. Italy Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 185. Italy Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 186. Italy Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 187. United Kingdom Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 188. United Kingdom Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 189. United Kingdom Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 190. Netherlands Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 191. Netherlands Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 192. Netherlands Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 193. Rest of Europe Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 194. Rest of Europe Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 195. Rest of Europe Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 196. MEA Next Generation Sequencing, by Country USD Billion (2022-2027)
  • Table 197. MEA Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 198. MEA Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 199. MEA Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 200. Middle East Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 201. Middle East Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 202. Middle East Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 203. Africa Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 204. Africa Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 205. Africa Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 206. North America Next Generation Sequencing, by Country USD Billion (2022-2027)
  • Table 207. North America Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 208. North America Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 209. North America Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 210. United States Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 211. United States Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 212. United States Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 213. Canada Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 214. Canada Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 215. Canada Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 216. Mexico Next Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 217. Mexico Next Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 218. Mexico Next Generation Sequencing, by End-Users USD Billion (2022-2027)
  • Table 219. Research Programs/Design for This Report
  • Table 220. Key Data Information from Secondary Sources
  • Table 221. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Next Generation Sequencing: by Type USD Billion (2016-2021)
  • Figure 5. Global Next Generation Sequencing: by Application USD Billion (2016-2021)
  • Figure 6. Global Next Generation Sequencing: by End-Users USD Billion (2016-2021)
  • Figure 7. South America Next Generation Sequencing Share (%), by Country
  • Figure 8. Asia Pacific Next Generation Sequencing Share (%), by Country
  • Figure 9. Europe Next Generation Sequencing Share (%), by Country
  • Figure 10. MEA Next Generation Sequencing Share (%), by Country
  • Figure 11. North America Next Generation Sequencing Share (%), by Country
  • Figure 12. Global Next Generation Sequencing share by Players 2021 (%)
  • Figure 13. Global Next Generation Sequencing share by Players (Top 3) 2021(%)
  • Figure 14. Global Next Generation Sequencing share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. DNAnexus [United States] Revenue, Net Income and Gross profit
  • Figure 17. DNAnexus [United States] Revenue: by Geography 2021
  • Figure 18. DNASTAR [United States] Revenue, Net Income and Gross profit
  • Figure 19. DNASTAR [United States] Revenue: by Geography 2021
  • Figure 20. Eagle Genomics [United Kingdom] Revenue, Net Income and Gross profit
  • Figure 21. Eagle Genomics [United Kingdom] Revenue: by Geography 2021
  • Figure 22. Edge Biosystems [United States] Revenue, Net Income and Gross profit
  • Figure 23. Edge Biosystems [United States] Revenue: by Geography 2021
  • Figure 24. GENEWIZ [United States] Revenue, Net Income and Gross profit
  • Figure 25. GENEWIZ [United States] Revenue: by Geography 2021
  • Figure 26. Roche [Switzerland] Revenue, Net Income and Gross profit
  • Figure 27. Roche [Switzerland] Revenue: by Geography 2021
  • Figure 28. Agilent Technologies [United States] Revenue, Net Income and Gross profit
  • Figure 29. Agilent Technologies [United States] Revenue: by Geography 2021
  • Figure 30. Biomatters, Ltd [New Zealand] Revenue, Net Income and Gross profit
  • Figure 31. Biomatters, Ltd [New Zealand] Revenue: by Geography 2021
  • Figure 32. CLC Bio [Denmark] Revenue, Net Income and Gross profit
  • Figure 33. CLC Bio [Denmark] Revenue: by Geography 2021
  • Figure 34. GATC biotech AG [Germany] Revenue, Net Income and Gross profit
  • Figure 35. GATC biotech AG [Germany] Revenue: by Geography 2021
  • Figure 36. Macrogen [South Korea] Revenue, Net Income and Gross profit
  • Figure 37. Macrogen [South Korea] Revenue: by Geography 2021
  • Figure 38. BGI (Beijing Genomics Institute) [China] Revenue, Net Income and Gross profit
  • Figure 39. BGI (Beijing Genomics Institute) [China] Revenue: by Geography 2021
  • Figure 40. Illumina [United States] Revenue, Net Income and Gross profit
  • Figure 41. Illumina [United States] Revenue: by Geography 2021
  • Figure 42. Life Technology Corporation [United States] Revenue, Net Income and Gross profit
  • Figure 43. Life Technology Corporation [United States] Revenue: by Geography 2021
  • Figure 44. EMC Corporation [United States] Revenue, Net Income and Gross profit
  • Figure 45. EMC Corporation [United States] Revenue: by Geography 2021
  • Figure 46. Dnastar [United States] Revenue, Net Income and Gross profit
  • Figure 47. Dnastar [United States] Revenue: by Geography 2021
  • Figure 48. Global Next Generation Sequencing: by Type USD Billion (2022-2027)
  • Figure 49. Global Next Generation Sequencing: by Application USD Billion (2022-2027)
  • Figure 50. Global Next Generation Sequencing: by End-Users USD Billion (2022-2027)
  • Figure 51. South America Next Generation Sequencing Share (%), by Country
  • Figure 52. Asia Pacific Next Generation Sequencing Share (%), by Country
  • Figure 53. Europe Next Generation Sequencing Share (%), by Country
  • Figure 54. MEA Next Generation Sequencing Share (%), by Country
  • Figure 55. North America Next Generation Sequencing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • DNAnexus [United States]
  • DNASTAR [United States]
  • Eagle Genomics [United Kingdom]
  • Edge Biosystems [United States]
  • GENEWIZ [United States]
  • Roche [Switzerland]
  • Agilent Technologies [United States]
  • Biomatters, Ltd [New Zealand]
  • CLC Bio [Denmark]
  • GATC biotech AG [Germany]
  • Macrogen [South Korea]
  • BGI (Beijing Genomics Institute) [China]
  • Illumina [United States]
  • Life Technology Corporation [United States]
  • EMC Corporation [United States]
  • Dnastar [United States]
Additional players considered in the study are as follows:
Thermo Fisher Scientific, Inc [United States] , Pacific Biosciences of California, Inc [United States] , Oxford Nanopore Technologies, Ltd. [United Kingdom] , Eurofins Scientific [Luxembourg] , PerkinElmer [United States] , Qiagen [Netherlands] , 454 Life Sciences [United States] , PierianDx [United States]
Select User Access Type

Key Highlights of Report


Feb 2024 246 Pages 74 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Next Generation Sequencing Market Quantitative research analysis
Global Next Generation Sequencing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Next Generation Sequencing Market are by type [Targeted Sequencing & Resequencing, Whole Genome Sequencing and Whole Exome Sequencing], by end use application [Whole-genome Sequencing, Exome Sequencing, Targeted Resequencing, De Novo Sequencing, RNA Sequencing, ChIP Sequencing, Methyl Sequencing and Others].
The Next Generation Sequencing Market is gaining popularity and expected to see strong valuation by 2027.
  • Technical Advancement in NGS platform
  • Ability to Provide Cost Effective Solution

Know More About Global Next Generation Sequencing Market Report?

Have a Query? Click Here

Other Related Reports

Ventilators Comprehensive Study by Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), Application (Hospitals and Clinics, Home Care, Ambulatory Care Centers, Emergency Medical Services ...
$ 3750
Forehead Thermometer Comprehensive Study by Type (Non-contact Type, Contact Type), Application (Hospital, Home Use, Others), Distribution Channel (Pharmaceuticals, Online Channel, Random Shops) Playe...
$ 3500
Fitness Equipment Comprehensive Study by Type (Strength Training Equipment (Weight Benches, Dumbbells, Resistance Bands, Others), Cardiovascular Training Equipment (Treadmills, Ellipticals, Stationar...
$ 3800
Bone Void Filler Comprehensive Study by Type (Demineralized Bone Matrix, Calcium Sulfate, Collagen Matrix, Hydroxyapatite, Tri Calcium Phosphate, Others), Application (Orthopedic surgery, Dental surg...
$ 3650
Coronary Catheters Comprehensive Study by Type (Aspiration Catheters , Coronary Balloon Catheters , Diagnostic Catheters , Guide Catheters, Electrophysiology Catheters, Non-Imaging Diagnostic Cathete...
$ 3750
Kidney Dialysis Equipment Comprehensive Study by Type (Hemodialysis (Hemodialysis Machines, Catheters, Dialyzers, Dialysates, Blood Pumps, Dialysis Tubing Kits, & Other Supplies), Peritoneal Dialysis...
$ 3750